CDK5 Antibody [H9D2] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat, Monkey

Usage Information

Dilution
WB1:1000 IP1:50 IF1:200 - 1:400

Application
WB, IP, IF

Reactivity
Human, Mouse, Rat, Monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
30 kDa

Positive Control	HeLa cells; Mouse retina; Mouse cortex; Mouse cerebellum
Negative Control

Datasheet & SDS

Biological Description

Specificity
CDK5 (D1F7M) Rabbit mAb detects endogenous levels of total CDK5 protein.

Clone
H9D2

Synonym(s)
Cyclin-dependent kinase 5; Cell division protein kinase 5; Tau protein kinase II catalytic subunit; TPKII catalytic subunit; CDK5; CDKN5; PSSALRE

Background
CDK5 is a proline‑directed serine/threonine kinase of the cyclin‑dependent kinase (CDK) family that uniquely functions primarily in post‑mitotic neurons rather than in cell cycle progression. It is activated by binding neuron‑specific, non‑cyclin cofactors p35 or p39, which induce conformational changes that expose the ATP‑binding cleft and key catalytic residues such as Lys33, Glu240, and Asp145 that are essential for phosphotransfer. CDK5 adopts the canonical bilobal kinase fold, with a conserved glycine‑rich loop (G‑loop) that positions the nucleotide, an activation loop containing atypical Thr14/Tyr15 phosphorylation sites for CDKs, and binding pockets for p35/p39 that sterically displace CDK5’s autoinhibitory helix αH. CDK5–p35/p39 activity regulates neuronal migration via N‑cadherin and microtubule dynamics (for example, by phosphorylating DCX), synaptic plastic Mans‑related plasticity and LTD via AMPA receptor trafficking. calpain‑mediated cleavage of p35 to p25 deregulates CDK5, causing hyperphosphorylation of tau (at sites such as Ser202/Thr205/Ser396), APP (Thr668), and neurofilaments. This promotes neurofibrillary tangle formation, Aβ‑42 production, synaptic loss, mitochondrial dysfunction, and apoptosis in Alzheimer’s disease (AD), while also contributing to α‑synuclein aggregation in Parkinson’s disease, huntingtin‑associated pathology in Huntington’s disease, and TDP‑43 mislocalization in amyotrophic lateral sclerosis (ALS).

Background

CDK5 is a proline‑directed serine/threonine kinase of the cyclin‑dependent kinase (CDK) family that uniquely functions primarily in post‑mitotic neurons rather than in cell cycle progression. It is activated by binding neuron‑specific, non‑cyclin cofactors p35 or p39, which induce conformational changes that expose the ATP‑binding cleft and key catalytic residues such as Lys33, Glu240, and Asp145 that are essential for phosphotransfer. CDK5 adopts the canonical bilobal kinase fold, with a conserved glycine‑rich loop (G‑loop) that positions the nucleotide, an activation loop containing atypical Thr14/Tyr15 phosphorylation sites for CDKs, and binding pockets for p35/p39 that sterically displace CDK5’s autoinhibitory helix αH. CDK5–p35/p39 activity regulates neuronal migration via N‑cadherin and microtubule dynamics (for example, by phosphorylating DCX), synaptic plastic Mans‑related plasticity and LTD via AMPA receptor trafficking. calpain‑mediated cleavage of p35 to p25 deregulates CDK5, causing hyperphosphorylation of tau (at sites such as Ser202/Thr205/Ser396), APP (Thr668), and neurofilaments. This promotes neurofibrillary tangle formation, Aβ‑42 production, synaptic loss, mitochondrial dysfunction, and apoptosis in Alzheimer’s disease (AD), while also contributing to α‑synuclein aggregation in Parkinson’s disease, huntingtin‑associated pathology in Huntington’s disease, and TDP‑43 mislocalization in amyotrophic lateral sclerosis (ALS).

References
https://pubmed.ncbi.nlm.nih.gov/24879856/ https://pubmed.ncbi.nlm.nih.gov/16407256/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%